Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics

Int Forum Allergy Rhinol. 2022 Mar;12(3):306-309. doi: 10.1002/alr.22900. Epub 2021 Oct 30.

Authors

Glen E D'Souza¹, Uche Nwagu¹, Blair Barton¹, Aykut A Unsal¹, Mindy R Rabinowitz^{1

2}, Marc R Rosen^{1

2}, Gurston G Nyquist^{1

2}, John Cohn³, Jessica Most⁴, Elina M Toskala¹

Affiliations

¹ Department of Otolaryngology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
² Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
³ Division of Pulmonary, Allergy and Critical Care Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
⁴ Department of Pulmonary and Respiratory Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

PMID: 34719120
DOI: 10.1002/alr.22900

No abstract available

Keywords: FESS; SNOT-22; asthma; chronic rhinosinusitis; endoscopic sinus surgery; eosinophilic rhinitis and nasal polyposis.

MeSH terms

Aspirin / adverse effects
Asthma, Aspirin-Induced* / therapy
Biological Products* / adverse effects
Chronic Disease
Desensitization, Immunologic
Humans
Nasal Polyps* / therapy
Rhinitis* / therapy
Sinusitis* / chemically induced
Sinusitis* / therapy

Substances

Biological Products
Aspirin